← boardnext 2029-06
PRTC
PureTechdistress 0/10 · well-funded / low risk$17.38+5%today-12% from 52w high
Lead: Idiopathic Pulmonary Fibrosis (IPF) · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$277M
Runway
3.3 yrs
Shares 1y
—
Price & events
-8.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.5%
1D
+4.5%
1W
+0.2%
1M
-5.0%
3M
-9.5%
6M
-6.1%
1Y
—
2Y
—
5Y
-10.8%
All
Overview
- Volume
- 9.86K
- 52 Week Range
- $14.50 – $19.84
- Float Shares
- 157.18M
- Short %
- 0.12%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.58%
- RVOL
- 6.60x
- Beta
- 0.79
Pipeline stages · 1 programs
Deupirfenidone, Pirfenidone (PFD)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 3 | Deupirfenidone, Pirfenidone (PFD) | Idiopathic Pulmonary Fibrosis (IPF) | — | not yet recruiting |
Catalyst news & presentations · 1
- 2026-08-27earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — Idiopathic Pulmonary Fibrosis (IPF)
- none identified
Recent news
- 2026-07-18PureTech Health: Results of Annual General Meeting - The National Law Review
- 2026-07-17PureTech Health Issues Vested RSU Shares to Senior Executives - TipRanks
- 2026-07-17PureTech Health issues shares to executives under vesting plan - Investing.com
- 2026-07-17REG - PureTech Health PLC - PDMR Notification RSU Vesting - TradingView
- 2026-07-13PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - BioSpace
- 2026-07-13PureTech Health announces first patient dosing in Celea phase 3 trial - London South East
- 2026-07-13PureTech’s Celea Starts Landmark Phase 3 Head-to-Head IPF Trial - TipRanks
- 2026-07-13REG - PureTech Health PLC - PRTC: Celea Doses 1st Patient in Phase 3 IPF Trial - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.